Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

A-M C. Dingemans; L. E. L. Hendriks

doi:10.1016/S2213-2600(19)30043-8

Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

A-M C. Dingemans^*, L. E. L. Hendriks

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

174 Downloads (Pure)

Original language	English
Pages (from-to)	291-292
Number of pages	2
Journal	The Lancet Respiratory medicine
Volume	7
Issue number	4
DOIs	https://doi.org/10.1016/S2213-2600(19)30043-8
Publication status	Published - Apr 2019

Keywords

PEMBROLIZUMAB

Access to Document

10.1016/S2213-2600(19)30043-8

Full TextFinal published version, 140 KBLicence: Taverne

Cite this

@article{d49dbe5d12e0465c8976d1db5fd20c12,

title = "Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?",

keywords = "PEMBROLIZUMAB",

author = "Dingemans, {A-M C.} and Hendriks, {L. E. L.}",

note = "Funding Information: LELH receives research funding from Roche and Boehringer Ingelheim, is on the advisory board of Boehringer Ingelheim and Bristol-Myers Squibb, receives travel reimbursement from Roche and Bristol-Myers Squibb, and is part of a mentorship programme with key opinion leaders funded by AstraZeneca. A-MCD is on the advisory board of Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Eli Lilly, Takeda, Pfizer, and Boehringer Ingelheim and receives a research grant from Bristol-Myers Squibb.",

year = "2019",

month = apr,

doi = "10.1016/S2213-2600(19)30043-8",

language = "English",

volume = "7",

pages = "291--292",

journal = "The Lancet Respiratory medicine",

issn = "2213-2600",

publisher = "ELSEVIER SCI LTD",

number = "4",

}

TY - JOUR

T1 - Immune checkpoint inhibitors in non-small-cell lung cancer

T2 - key to long-term survival?

AU - Dingemans, A-M C.

AU - Hendriks, L. E. L.

N1 - Funding Information: LELH receives research funding from Roche and Boehringer Ingelheim, is on the advisory board of Boehringer Ingelheim and Bristol-Myers Squibb, receives travel reimbursement from Roche and Bristol-Myers Squibb, and is part of a mentorship programme with key opinion leaders funded by AstraZeneca. A-MCD is on the advisory board of Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Eli Lilly, Takeda, Pfizer, and Boehringer Ingelheim and receives a research grant from Bristol-Myers Squibb.

PY - 2019/4

Y1 - 2019/4

KW - PEMBROLIZUMAB

U2 - 10.1016/S2213-2600(19)30043-8

DO - 10.1016/S2213-2600(19)30043-8

M3 - Editorial

SN - 2213-2600

VL - 7

SP - 291

EP - 292

JO - The Lancet Respiratory medicine

JF - The Lancet Respiratory medicine

IS - 4

ER -